[
1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727-33.10.1056/NEJMoa2001017
]Search in Google Scholar
[
2. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12(4):372.10.3390/v12040372
]Search in Google Scholar
[
3. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288(2):192-206.10.1111/joim.13091
]Search in Google Scholar
[
4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383(27):2603-15.10.1056/NEJMoa2034577
]Search in Google Scholar
[
5. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 – Preliminary Report. N Engl J Med 2020;383(20):1920-31.10.1056/NEJMoa2022483
]Search in Google Scholar
[
6. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396(10249):467-78.10.1016/S0140-6736(20)31604-4
]Search in Google Scholar
[
7. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021;384(23):2187-201.10.1056/NEJMoa2101544
]Search in Google Scholar
[
8. Pardi N, Muramatsu H, Weissman D, Karikó K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol 2013;969:29-42.10.1007/978-1-62703-260-5_2
]Search in Google Scholar
[
9. Davis FF. The origin of pegnology. Adv Drug Deliv Rev 2002;54(4):457-8.10.1016/S0169-409X(02)00021-2
]Search in Google Scholar
[
10. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021;6(12):1078-94.10.1038/s41578-021-00358-0835393034394960
]Search in Google Scholar
[
11. Latanova AA, Petkov S, Kilpelainen A, Jansons J, Latyshev OE, Kuzmenko YV, et al. Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity. Sci Rep 2018;8(1):8078.10.1038/s41598-018-26281-z
]Search in Google Scholar
[
12. Svitkin YV, Cheng YM, Chakraborty T, Presnyak V, John M, Sonenberg N. N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res 2017;45(10):6023-36.10.1093/nar/gkx135
]Search in Google Scholar
[
13. Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008;16(11):1833-40.10.1038/mt.2008.200
]Search in Google Scholar
[
14. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov 2018;17(4):261-79.10.1038/nrd.2017.243
]Search in Google Scholar
[
15. Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM Jr, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science 2020;369(6511):1586-92.10.1126/science.abd4251
]Search in Google Scholar
[
16. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384(15):1412-23.10.1056/NEJMoa2101765
]Search in Google Scholar
[
17. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet 2021;397(10277):875-7.10.1016/S0140-6736(21)00448-7
]Search in Google Scholar
[
18. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021;385(2):187-9.10.1056/NEJMc2104974
]Search in Google Scholar
[
19. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021;385(7):585-94.10.1056/NEJMoa2108891
]Search in Google Scholar
[
20. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021;398(10309):1407-16.10.1016/S0140-6736(21)02183-8
]Search in Google Scholar
[
21. Barda N, Dagan N, Cohen C, Hernán MA, Lipstich M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021;398(10316):2093-100.10.1016/S0140-6736(21)02249-2
]Search in Google Scholar
[
22. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021;385(15):1393-400.10.1056/NEJMoa2114255
]Search in Google Scholar
[
23. Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 Months. N Engl J Med 2021;385(19):1761-73.10.1056/NEJMoa2110345
]Search in Google Scholar
[
24. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2021;385(12):1078-90.10.1056/NEJMoa2110475
]Search in Google Scholar
[
25. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med 2021;385(23):2140-9.10.1056/NEJMoa2109730
]Search in Google Scholar
[
26. Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after Covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ 2021;374:n1931.10.1136/bmj.n1931
]Search in Google Scholar
[
27. Hause AM, Baggs J, Marquez P, Myers TR, Su JR, Blanc PG, et al. Safety monitoring of COVID-19 vaccine booster doses among adults – United States, September 22, 2021–February 6, 2022. MMWR Morb Mortal Wkly Rep 2022;71(7):249-54.10.15585/mmwr.mm7107e1
]Search in Google Scholar
[
28. Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021;398(10318):2258-76.10.1016/S0140-6736(21)02717-3
]Search in Google Scholar
[
29. Xu S, Huang R, Sy LS, Glenn SC, Ryan DS, Morrissette K, et al. COVID-19 Vaccination and Non-COVID-19 Mortality Risk – Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021. MMWR Morb Mortal Wkly Rep 2021;70(43):1520-4.10.15585/mmwr.mm7043e2855302834710075
]Search in Google Scholar
oraz 